Cumulative thalidomide exposure, peripheral neuropathy, and clinical outcomes in pediatric and very early-onset inflammatory bowel disease: a retrospective cohort study

Jing Mao, Pan Li, Zebin Chen, Zhongqiang Cao, Ling Yang, Zhuyin Li, Zhaoxia Wang, Shuo Liang · 2026

Read Cumulative thalidomide exposure, peripheral neuropathy, and clinical outcomes in pediatric and very early-onset inflammatory bowel disease: a retrospective cohort study by Jing Mao, Pan Li, Zebin Chen, Zhongqiang Cao, Ling Yang, Zhuyin Li, Zhaoxia Wang, Shuo Liang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13578953.txt.

Description

Jing Mao and co-authors study the link between total thalidomide dose and nerve damage in children with inflammatory bowel disease, in work published in 2026. The drug is a rescue option for children whose disease resists standard care. Its main limit is nerve damage in the limbs, which grows with exposure.

The study reviewed 49 children treated at one centre over seven years. About a quarter developed nerve damage. Those who did had received much higher total doses than those who did not. A threshold dose predicted nerve damage with fair accuracy. Children with the very-early-onset form of the disease had fewer side effects overall than older children, with no clear gap in nerve damage. The authors propose the threshold as a guide for dosing and monitoring.

Catalog record

CREATORJing Mao, Pan Li, Zebin Chen, Zhongqiang Cao, Ling Yang, Zhuyin Li, Zhaoxia Wang, Shuo Liang
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE30 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13578953

Browse the full library · About the Tower of Babel